SOLENO THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.48 USD | +5.17% |
|
+3.88% | -2.47% |
| Apr. 04 | Soleno Therapeutics Insider Sold Shares Worth $784,645, According to a Recent SEC Filing | MT |
| Mar. 18 | North American Morning Briefing : Investors -2- | DJ |
Presenter SpeechJames MacKaness (Executives)Good morning, ladies and gentlemen. I am Jim MacKa...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCRâs mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
37.54
USD
Average target price
64.33
USD
Spread / Average Target
+71.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.47% | 1.22B | |
| -0.54% | 103B | |
| +3.40% | 96.73B | |
| +1.66% | 21.31B | |
| -16.50% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -23.78% | 13.68B | |
| +5.90% | 13.44B | |
| +22.72% | 10.98B |
- Stock Market
- Equities
- SLNO Stock
- News Soleno Therapeutics, Inc.
- Transcript : Soleno Therapeutics, Inc. - Shareholder/Analyst Call
